Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A. Scarlett, M.D ...

FOSTER CITY, Calif., March 11, 2025--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer ...

Geron (GERN) Corporation announced that the European Commission has granted marketing authorization for RYTELO as a monotherapy for the treatment of adult patients with transfusion-dependent ...

Geron (GERN) Corporation announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new ...

(RTTNews) - Geron Corporation (GERN), a commercial-stage biopharmaceutical company, announced that President, Chief Executive Officer and Chairman John Scarlett will depart from the company on ...

Geron has launched a search for a new chief executive, as John Scarlett plans to step down from the company's top role, effective March 31. At that time, Scarlett will additionally step down from ...

FOSTER CITY, Calif. - Geron Corporation (NASDAQ:GERN), a $1.03 billion market cap biopharmaceutical company specializing in blood cancer treatments, announced today the departure of Dr. John "Chip" A.

The company won the first drug approval in its 34-year history, but sales flattened toward the end of last year. John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp ...

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institute for ...

Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS) drug candidate imetelstat. A briefing document (PDF ...

After hours: March 14 at 7:59:53 PM EDT Loading Chart for GERN ...